focus -WSS

focus

author：comprehensive 2025-09-28 01:38:23 - browse：7

A doctor climbs up a red ladder to a vine shaped like a DNA — biotech coverage from STAT — Adobe

Every morning, Victoria Rasberry gets up before 6 a.m., walks to the bedroom down the hall, and helps her 8-year-old daughter Addi slide into a set of contraptions that squeeze and suck out the thick mucus constantly threatening to choke her airways closed. She feeds Addi breakfast through a stomach tube and makes sure she has the right mix of the 28 different medications required to keep her free of pain, infections, and seizures. At some point, Rasberry’s five other children will wake up and start to get ready for school, including her youngest, Oliver. At 3-and-a-half years old, he’s a typical toddler — always running and giggling and getting into things. You would never know that he and Addi were born with the same mutation lurking in their DNA, a genetic glitch that causes a fatal neurodegenerative disease called metachromatic leukodystrophy, or MLD.

“When Addi was this age she had lost the ability to speak and was already using a ventilator to sleep at night,” Rasberry said. “It’s amazing to see how well Ollie is doing in comparison. And it’s all because of the gene therapy.”

Three years ago, when Ollie was just 6 months old, he and Victoria traveled from their home in Texas to Milan, to receive a gene therapy treatment that adds a healthy version of the defective gene into patients’ own stem cells. At the time, traveling abroad for the therapy, which is manufactured by Orchard Therapeutics and was approved in Europe in 2021, was the only option for families stricken by MLD. But soon it will be available in the U.S., too.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Questions and answers about ramping up H5N1 bird flu vaccine

focus

WSS

Leukemia patients are helped by Syndax's new type of therapy

Teach medical students about patients with intellectual disabilities

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Digital health: a case of mistaken identity

FDA approves world's first CRISPR

focus

focus

knowledge

What does generative AI mean for health care? We asked experts

Cue Health, Covid

Activists slam private health insurers over coverage restrictions

In diabetes hearing, Sanders takes on a new foe: food makers

After affirmative action ruling, medical educators look to 'holistic review'

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

After affirmative action ruling, medical educators look to 'holistic review'

H5N1 virus can be tracked in retail milk, scientists say

In age of alternative facts, a scholarly course on calling out crap

Patients' immediate access to test results puts radiologists in a bind

focus

Pregnancy discrimination could be enabled by AI

Eyeing GLP

Why sickle cell disease is getting the first CRISPR treatment

ASCO eve: Let’s set the table for this year's meeting

Biogen joins immunology wave with $1.15 billion acquisition of HI

FDA approves world's first CRISPR

explore

focus

knowledge

leisure time